Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 4/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | NPY1R | P25929 | 2/20 | 0.46 |
| ▸ | NPY4R | P50391 | 2/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | SCTR | P47872 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460678 | 1.00 | TFPI (0.54) | TFPIRXFP1OPRM1OPRK1NPY5R | |
| SCHEMBL29659755 | 0.90 | GLP1R (0.47) | TFPINPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL30930088 | 0.87 | FURIN (0.46) | TFPIOPRM1OPRK1 | |
| SCHEMBL6035701 | 0.87 | OPRM1 (0.58) | TFPIOPRM1OPRK1NPY5RNPY1R | |
| SCHEMBL29659741 | 0.87 | NPY4R (0.47) | NPY5RNPY1RNPY4RGLP1RSCTR | |
| SCHEMBL16976068 | 0.86 | TFPI (0.59) | TFPINPY5RNPY1RNPY4RNR3C1 | |
| SCHEMBL14479450 | 0.86 | TFPI (0.59) | TFPINPY5RNPY1RNPY4RNR3C1 | |
| SCHEMBL29659733 | 0.86 | C5AR1 (0.53) | TFPINPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL29659782 | 0.85 | NPY4R (0.48) | NPY5RNPY1RNPY4RGLP1RSCTR | |
| SCHEMBL14479369 | 0.85 | GLP1R (0.50) | TFPIRXFP1NPY5RNPY1RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350578-A1 | FUNCTIONAL OUTCOMES AFTER SPINAL CORD INJURY | DUKE UNIVERSITY | 2024-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350578-A1 | FUNCTIONAL OUTCOMES AFTER SPINAL CORD INJURY | SMN1; SMN2, CSTB, BDNF | TFPI 1386/4885RXFP1 101/4885OPRM1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.